Januvia family becomes King of ETC drugs over other antidiabetics

Published: 2016-03-28 16:01:10

Updated: 2016-03-28 16:01:10

MSD Korea’s(CEO Dong-wook Hyun) diabetes type 2 treatments, the Januvia family has made the top of the 2015 4^th quarter’s ETC market(based on the IMS’s amount of outpatient prescriptions).

The Januvia family, consisting of Januvia, a single sitagliptin DPP-4 inhibitor, Janumet, a sitagliptin/metformin complex, and Janumet XR, a complex combining sitagliptin and a release-type metformin, record...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.